Anti-leukocyte adhesion for the mitigation of potential adverse events caused by CD3-specific binding domains
摘要
<p>The present invention relates in essence to a compound which decreases or inhibits the binding of mammalian T-cells to mammalian endothelial cells for use in a method of prophylaxis and/or amelioration and/or treatment of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells in a patient. Methods of treatment of patients having or being at risk of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells are also contemplated.</p>
申请公布号
AU2014214020(A1)
申请公布日期
2015.07.30
申请号
AU20140214020
申请日期
2014.02.07
申请人
AMGEN RESEARCH (MUNICH) GMBH
发明人
KUFER, PETER;KLINGER, MATTHIAS;HOFFMANN, PATRICK;NAEGELE, VIRGINIE;DOPFER, ELAINE-PASHUPATI;NAGORSEN, DIRK;SCHEELE, JUERGEN;ZUGMAIER, GERHARD